
NTHI Stock Forecast & Price Target
NTHI Analyst Ratings
Bulls say
NeOnc Technologies Hldgs is pursuing innovative treatments for brain cancers, with a strong focus on improving drug delivery methods and candidate compounds. Despite the inherent risks of being a clinical-stage biopharmaceutical company, NeOnc has shown promise in preclinical and clinical studies and has key catalysts expected in the near future. However, the company may face financial challenges due to a potentially higher cost of bridge loans and ongoing development of their drug delivery technology.
Bears say
NeOnc Technologies Hldgs is facing fundamental risks as their drugs, while promising in tackling CNS diseases, have technical complexities in dosage determination and potential safety issues with repeated dosing. Additionally, their focus on utilizing Perillyl alcohol (POH) to cross the blood-brain barrier (BBB) may not be as effective in all CNS tumors, potentially limiting the success of their lead products NEO100 and NEO212. Furthermore, there are still uncertainties surrounding the effectiveness and safety of their drugs in clinical trials, and the limited eligibility and high relapse rates of patients for the current standard of care treatment may also pose challenges.
This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
NTHI Analyst Forecast & Price Prediction
Start investing in NTHI
Order type
Buy in
Order amount
Est. shares
0 shares